Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Healthy: early-phase trial registry
225 of 1,096 indexed Healthy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2 of 28,707 conditions by registered trial count.
1,096 US clinical trials · 225 currently recruiting · #2 of 28,707 conditions by registered trial count
Healthy: 1,096 US clinical trials tracked, 225 recruiting.
Healthy is the subject of 1,096 registered US clinical trials on ClinicalTrials.gov, 225 of them currently open to new participants. 43 are in Phase 3-4 (later-stage) and 546 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 55 of these trials.
Enrollment posture brief
Registry condition healthy
OPEN 225 | RECR 21% | LATE 43 | EARLY 546 | RANK #2 | SPON 55
Volume-matched condition peers
Nearest open-share peer: Psoriasis (20% recruiting · 127 trials)
Healthy lists 225 open slots (21% of 1,096 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Healthy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Healthy is recruiting below its size-band peers.
225 of 1,096 indexed trials (20.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Healthy trials is spread across many organizations.
Eli Lilly and Company accounts for 55 of 1,096 trials (5%). 429 distinct sponsors appear on at least one study for this condition label.
-
Most Healthy trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 1,091 trials that report a genuine target (sentinel values excluded). 851 of those (78%) plan for fewer than 100 participants.
-
Healthy research is mostly interventional.
905 interventional and 191 observational studies make up this index (82.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,096 total, page 20 of 22
Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers
Pain Therapeutics
NCT02165930
Evaluation of a Neck Strengthening Program to Reduce the Risk of Sport-related Concussion
University of Michigan
NCT02455037
Amino Acid Profile and Muscle Protein Synthetic Response to Consuming Meat or Plant-based Alternatives
University of California, Davis
NCT04784806
Effects of Tolvaptan in Healthy Adults
Northwestern University
NCT01973140
The Effect of Cinacalcet on Gastric Acid Output in Healthy Subjects
Tufts University
NCT00336739
Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production
Cerecin
NCT03063645
A Study of [¹⁴C]-LY3484356 in Healthy Female Participants
Eli Lilly and Company
NCT04991766
A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects
Pfizer
NCT02208284
PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT02553356
Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction
Alexion Pharmaceuticals
NCT04935294
A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants
Bristol-Myers Squibb
NCT03936374
Evaluation of PK of AC-1204 Mixed in Water, AC-1202 Mixed in Water, and AC-1202 Mixed in Ensure® on Ketone Body Production
Cerecin
NCT02959710
A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants
Eli Lilly and Company
NCT05338476
Accuracy of Noninvasive Pulse Oximeter Sensor (MightySat RX)
Masimo Corporation
NCT03125135
Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam
Emalex Biosciences
NCT01408394
A Study of Lithium and Enlicitide in Healthy Adult Participants (MK-0616-034)
Merck Sharp & Dohme
NCT06719544
T Cell Responses to Various Levels of Exercise Stress
University of Kansas
NCT06638684
A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)
Merck Sharp & Dohme
NCT07222098
Study to Assess Blood Levels of Itraconazole During a Two-Week Period
Stiefel, a GSK Company
NCT00695071
A Target Occupancy Study With Ritlecitinib.
Pfizer
NCT05128058
Developing a Biomarker Panel to Assess Choline Nutritional Status
University of North Carolina, Chapel Hill
NCT03234062
A Study of [14C]-LY4065967 in Healthy Participants
Eli Lilly and Company
NCT07039045
Multi-organ Transit Time Acquisition Using Contrast Ultrasound
Vanderbilt University Medical Center
NCT05135169
Phase I Study of PSD502 (Lidocaine Prilocaine Spray) Applied to the Glans Penis up to Three Times a Day for 21 Days in Healthy Male Volunteers
Plethora Solutions
NCT00483990
Human Perception on Medical Extended Reality Devices
Food and Drug Administration (FDA)
NCT05479019
Meals and Grazing Study
Fred Hutchinson Cancer Center
NCT02548026
A Study of [14C]-LY3866288 in Healthy Participants
Eli Lilly and Company
NCT06644378
Phyllantus Amarus for the Protection of Liver Health
Biotropics Malaysia Berhad
NCT03349697
Acute Effect of Three Neuroactive Drugs Measured by Magnetoencephalography (MEG), Electroencephalography (EEG) and the Synchronous Neural Interaction Test
Orasi Medical
NCT00972985
Mobile Cardiac Telemetry (MCT) Study
Baxter Healthcare Corporation
NCT07158333
Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Compared to Patients With Established RA, and Normal Subjects
Orrin M Troum, M.D. and Medical Associates
NCT01499732
Pharmacokinetic Study of SP-103 in Healthy Adult Human Subjects
Scilex Pharmaceuticals
NCT04819581
Study to Evaluate the Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in Elderly Subjects
Massachusetts General Hospital
NCT01274598
Exploratory Study Using Positron Emission Tomography With TS-121 and [11C]TASP0410699 in Healthy Adult Male Subjects
Taisho Pharmaceutical R&D
NCT02448212
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants
Eli Lilly and Company
NCT06180967
Vaccine to Prevent West Nile Virus Disease
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00106769
A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers
Pfizer
NCT01677065
Bioavailability of Golden Rice Carotenoids in Humans
Tufts University
NCT00680355
Glycemic Index of Table Grape Varietals
University of California, Davis
NCT03248609
Non-intrusive Detection of Temporary Neurologic Impairment By Opioids
Mayo Clinic
NCT04223609
A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling
Pfizer
NCT05948085
A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT02492776
The Effects of Pre-Loaded Betaine Supplementation on Thermoregulation and Exercise Metabolism in the Heat
Florida State University
NCT04585295
Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145
SecuraBio
NCT01947777
Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adults
Genzyme, a Sanofi Company
NCT01659944
Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam
SecuraBio
NCT01925911
A Phase I Study to Assess the Pharmacokinetics of Metformin When Administered Alone and in Combination With Vandetanib
Sanofi
NCT01551615
Desaturation Validation of INVSENSOR00038
Masimo Corporation
NCT04017611
Controlled Acute Hypoxia Study - Abbreviated Sensor Line
Medtronic - MITG
NCT02216344
KickStart30: A 30-Day Intervention for Patients With Rheumatoid Arthritis (RA)
University of Texas at Austin
NCT03993548
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 518 |
| Phase 2 | 28 |
| Phase 3 | 11 |
| Phase 4 | 32 |
Top Sponsors
Named interventions
Most-linked intervention names on Healthy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Healthy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Healthy page
1,096 registered trials, 225 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 225 Healthy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Healthy trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Healthy condition card totals 1,096 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.